|
|
|
LifeScienceHistory.com - Check us out on Instagram
Massachusetts Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MassachusettsLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Enumeral Biomedical Holdings, Inc.
| | | Phone: | 617) 945-9146 | Year Established: | 2014 | Ticker: | ENUM | Exchange: | OTCQB | Main Contact: | Wael Fayad, Chairman, President & CEO | | Other Contacts: | Matthew A. Ebert, General Counsel Kevin Sarney, VP, Finance & Chief Accounting Officer
| | Company Description | Enumeral is a biopharmaceutical company focused on the discovery and advancement of next generation therapeutics in cancer, auto-immune, and other diseases. The Company utilizes a proprietary microwell array technology to identify cell type and measure functioning of individual cells from tissue samples, and to retrieve individual live cells of interest, for cell culture or gene cloning. This technology provides key insights for target validation, drug candidate selection, and rational drug development. The company has built a pipeline of immune checkpoint modulators for targets including PD-1, TIM-3, CD39, and others. | |
|
|
|
|
|